運動禁藥―蛋白酵素之違規摻假

Prohibited Substances of Protease in Doping

10.6162/SRR.2012.123.10

楊惠茹(Huei-Ru Yang)；許美智(Mei-Chich Hsu)

人類絨毛膜性腺激素 ； 基因重組人類紅血球生成素 ； 胰島素 ； 胜肽類荷爾蒙 ； 世界運動禁藥管制機構 ； human chorionic gonadotropin ； recombinant human erythropoietin ； insulin ； peptide hormone ； World Anti-Doping Agency

大專體育

123期（2012 / 12 / 01）

71 - 77

繁體中文

在運動禁藥管制作業採樣過程中，尿液樣本的操控已經成為很嚴重的問題，包括刻意在尿液中加入蛋白酵素，使樣本中的胜肽類荷爾蒙，例如：人類絨毛膜性腺激素（human chorionic gonadotropin），基因重組人類紅血球生成素（recombinant human erythropoietin）及胰島素（insulin）等，被分解或複雜化，以掩蓋使用違禁物質之事實。世界運動禁藥管制機構（World Anti-Doping Agency, WADA）於2010年將蛋白酵素列入運動禁藥清單中，為避免運動員在運動禁藥採樣過程中加入蛋白酵素進而破壞尿液樣本的完整性，建立一個標準檢測流程或是預防的方法是非常重要的。本文將介紹蛋白酵素的生理特性、發展及應用、運動員使用蛋白酵素之方法及蛋白酵素之分析檢驗方法。

Manipulation of urinary samples in sports drug testing with proteases is being used by athletes as masking agents to complicate and prevent the detection of peptide hormones and proteins such as human chorionic gonadotropin (hCG), recombinant human erythropoietin (rHuEPO), or insulin. World Anti-doping Agency (WADA) is now included the protease on the doping control list since 2010. To avoid the use of protease, it is very important to establish a standard testing process. The proteases in the physiological properties, development and application, the manipulation by athletes, and analytical methods are introduced in this review.

1. News Feature. (2006, October 11). Beating the cheater. Retrieved March 20, 2012, from http://autobus.cyclingnews.com/features/?id=2006/epo_protease
2. The Original Macbeth of Blogs. (2009, May 8). Cabreira successfully appeals protease charge, 2nd time lucky. Retrieved March 20, 2012, form http://klausenrussell.com/WordPress/?p=2189
3. Weislo, L. (2009, May 8). Vaughter: Our season starts now. Retrieved October 12, 2011, from http://autobus.cyclingnews.com/news.php?id=news/2009/may09/may08news
4. World Anti-Doping Agency. (2010, January 1). The 2010 prohibited list international standard. Retrieved April 21, 2011, from http://www.wada-ama.org/Documents/World_Anti-Doping_Program/WADPProhibited-list/WADA_Prohibited_List_2010_EN.pdf
5. Basak, A.,Chen, A.,Majumdar, S.,Smith, H. P.(2011).In vitro assay for protease activity of proprotein convertase subtilisin kexins (PCSKs): Aan overall review of existing and new methodologies.Methods in Molecular Biology,768,127-153.
6. Elliott, S.(2008).Erythropoiesis-stimulating agents and other methods to enhance oxygen transport.British Journal of Pharmacology,154(3),529-541.
7. Jarerat, A.,Tokiwa, Y.(2003).Poly(L-lactide) degradation by Saccharothrix waywayandensis.Biotechnology Letters,25(5),401-404.
8. Lamon, S.,Robinson, N.,Sottas, P.,Henry, H.,Kamber, M.,Mangin, P.(2007).Possible origins of undetectable EPO in urine samples.Clinica Chimica Acta,385(1-2),61-66.
9. Lasne, F.,Martin, L.,Crepin, N.,de Ceaurriz, J.(2002).Detection of isoelectric profiles of erythropoietin in urine: Differentiation of natural and administered recombinant hormones.Analytical Biochemistry,311(2),119-126.
10. Leigh-Smith, S.(2004).Blood boosting.British Journal of Sports Medicine,38(1),99-101.
11. Nakamura, K.,Tomita, T.,Abe, N.,Kamio, Y.(2001).Purification and characterization of an extracellular poly(L-lactic acid) depolymerase from a soil isolate, Amycolatopsis sp. strain K104-1.Applied and Environmental Microbiology,67(1),345-353.
12. Oh, J.,Pyo, J. H.,Jo, E. H.,Hwang, S. I.,Kang, S. C.,Jung, J. H.(2004).Establishment of a nearstandard two-dimensional human urine proteomic map.Proteomics,4(11),3485-3497.
13. Pascual, J. A.,Belalcazar, V.,de Bolos, C.,Gutiérrez, R.,Llop, E.,Segura, J.(2004).Recombinant erythropoietin and analogues: A challenge for doping control.Theraputic Drug Monitoring,26(2),175-179.
14. Reichel, C.(2011).Recent developments in doping testing for erythropoietin.Analytical and Bioanalytical Chemistry,401(2),463-481.
15. Sanchis-Gomar, F.,Martinez-Bello, V. E.,Nascimento, A. L.,Gomez-Cabrera, M. C.,Viña, J.(2010).Alternate methods to prevent protease use as a masking agent in sport.Journal of Science and Medicine in Sport,13(5),473-474.
16. Spahr, C. S.,Davis, M. T.,McGinley, M. D.,Robinson, J. H.,Bures, E. J.,Beierle, J.(2001).Towards defining the urinary proteome using liquid chromatography-tandem mass spectrometry. I. Profiling an unfractionated tryptic digest.Proteomics,1(1),93-107.
17. Thevis, M.,Maurer, J.,Kohler, M.,Geyer, H.,Schänzer, W.(2007).Proteases in doping control analysis.International Journal of Sports Medicine,28(7),545-549.
18. Thomas, A.,Kohler, M.,Walpurgis, K.,Schänzer, W.,Thevis, M.(2009).Proteolysis and autolysis of proteases and the detection of degradation products in doping control.Drug Testing and Analysis,1(2),81-86.
19. Tsivou, M.,Dimopoulou, H. A.,Georgakopoulos, D. G.,Koupparis, M. Α.,Atta-Politou, J.,Georgakopoulos, C. G.(2010).Stabilization of human urine doping control samples: IV. Human chorionic gonadotropin.Analytical and Bioanalytical Chemistry,398(3),1313-1318.
20. Tsivou, M.,Dimopoulou, H. A.,Leontiou, I. P.,Georgakopoulos, D. G.,Koupparis, M. Α.,Atta-Politou, J.(2010).Stabilization of human urine doping control samples: III. Recombinant human erythropoietin.Clinica Chimica Acta,411(5-6),448-452.
21. Tsivou, M.,Livadara, D.,Georgakopoulos, D. G.,Koupparis, M. Α.,Atta-Politou, J.,Georgakopoulos, C. G.(2009).Stabilization of human urine doping control samples: II. Microbial degradation of steroids.Analytical Biochemistry,388(1),146-154.

1. 孫佳婷(2021)。基因與細胞禁藥治理－一個STS取向的考察。運動文化研究，39，33-78。